Viatris signs agreements with Biocon on $815m stake sale
The deal is anticipated to be finalised in the first quarter of 2026, pending the fulfilment of all closing conditions.
Drug Development
Agilent and Monash University Malaysia to set up biodiscovery hub
Formosa and Rxilient sign licensing agreement for APP13007
FDA approves Eli Lilly’s Jaypirca in relapsed or refractory CLL/SLL
AGC Biologics to expand cell line development with ATUM partnership
Citizen Health and UCB collaborate for epilepsy drug development
Solid Biosciences’ SGT-212 gains FDA rare paediatric disease status
Lotus submits NDA for VIZZ in South Korea to treat presbyopia
